ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

Celgene to pay Evotec $65 million in cancer drug pact

by Ryan Cross
May 27, 2018 | APPEARED IN VOLUME 96, ISSUE 22

 

Celgene has struck another long-term drug discovery deal with Evotec, a contract research firm in Hamburg, Germany. For an up-front payment of $65 million, Evotec will apply its phenotypic screening platform and compound libraries to discovering drugs for solid tumors. No details about milestone payments were disclosed. Celgene says it is pleased with a partnership it formed with Evotec in December 2016 in which it paid $45 million for neurodegenerative disease drug discovery.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment